...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Upcoming Zenith Events
Reply New Message
Prev Message Back To Forum Threaded View Next Message

The poster entitled "The BET Inhibitor ZEN-3694 Blocks Multiple Tumor Immune Suppressive Factors and has the Potential to Increase the Efficacy of Anti-PD1 Treatment" is available on the Zenith website or can be accessed here.

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply